Midha K K, Ormsby E D, Hubbard J W, McKay G, Hawes E M, Gavalas L, McGilveray I J
College of Pharmacy, University of Saskatchewan, Saskatoon, Canada.
J Pharm Sci. 1993 Feb;82(2):138-44. doi: 10.1002/jps.2600820205.
The rationale for using the logarithmic transformation on concentration-dependent pharmacokinetic parameters a priori is presented. This rationale is based on theoretical pharmacokinetic and statistical grounds, but is also applicable to the practice of physicians in dealing with variations of drug treatment within and between patients. The implications of the transformation on data analysis, specifically analysis of variance, and estimation and inference from the analysis as it pertains to bioequivalence decisions are explored. Implementation of the transformation is shown, with an example of two perphenazine formulations in a single-dose crossover study. It is concluded that the transformation has to be accepted on theoretical grounds because sample sizes are too small in bioequivalence studies and too susceptible to extreme values to state with any certainty the actual distribution of pharmacokinetic parameters or their differences within a subject.
本文阐述了对浓度依赖性药代动力学参数预先进行对数转换的基本原理。该原理基于理论药代动力学和统计学依据,同时也适用于医生在处理患者个体内及个体间药物治疗差异时的实际应用。探讨了这种转换对数据分析(特别是方差分析)以及与生物等效性决策相关的分析估计和推断的影响。通过单剂量交叉研究中两种奋乃静制剂的实例展示了该转换的实施过程。得出的结论是,基于理论依据必须接受这种转换,因为在生物等效性研究中样本量过小,且极易受到极端值的影响,以至于无法确切说明药代动力学参数在个体内的实际分布情况或它们之间的差异。